Clinical Trial Update: Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating TSR-033 in combination with an anti-PD-1 therapy in participants with advanced solid tumors has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• TSR-033

Snippet

Sponsor: Tesaro, Inc. | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2024-02-12